LRP5 and prostate cancer: In support, LRP5 knockdown in PC-3 cells reduced tumor burden and skeletal metastasis in xenografts [120], and small molecule inhibitors that reduce LRP6 expression and phosphorylation (e.g., niclosamide, salinomycin, and silibinin) can inhibit prostate cancer cell growth and increase apoptosis (reviewed in [118]).